European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision
- 1 September 2010
- journal article
- guideline
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 15 (3), 185-195
- https://doi.org/10.1111/j.1529-8027.2010.00278.x
Abstract
The aim of this guideline is to update the 2006 EFNS/PNS guideline on management of patients with a demyelinating neuropathy and a paraprotein (paraproteinemic demyelinating neuropathy [PDN]) by review of evidence and expert consensus. In the absence of adequate evidence, the panel agreed on good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) a monoclonal gammopathy of undetermined significance is more likely to be causing the neuropathy if it is immunoglobulin (Ig)M, anti-neural antibodies are present, and the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal sensory impairment, prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN may respond to immunomodulatory therapies. Their potential benefit should be balanced against possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy; and (6) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes syndrome is a multi-system malignant PDN.Keywords
This publication has 63 references indexed in Scilit:
- Rituximab for polyneuropathy with IgM monoclonal gammopathyJournal of Neurology, Neurosurgery & Psychiatry, 2009
- LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHYNeurology, 2008
- Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin MJournal of the Peripheral Nervous System, 2007
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgMJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Peripheral neuropathy in IgM monoclonal gammopathy and wäldenstrom's macroglobulinemia: A frequent complication in elderly males with low MAG‐reactive serum monoclonal componentAmerican Journal of Hematology, 1994